Novo Nordisk Launches World's First Once-Weekly Basal Insulin Awiqli in India
Danish pharmaceutical company Novo Nordisk has launched Awiqli (insulin icodec), the world's first once-weekly basal insulin, in India for adults with Type 1 and Type 2 diabetes. This therapy reduces insulin injections from 365 to 52 annually, aiming to ease injection-related anxiety and improve adherence. Priced competitively, Awiqli addresses barriers to insulin initiation, which is often delayed in India due to fear and cost. The launch marks India as the seventh country to introduce this treatment amid rising diabetes prevalence.
First-hand measurement across 8 sources
We measured how 8 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is positive (74/100). Lens Score 30/100 — low public interest.
Outlets analysed (first-hand measurement by TBN's Bias Engine):
- hindustantimes— balanced framing, positive sentiment
- businessstandard— balanced framing, positive sentiment
- firstpost— balanced framing, positive sentiment
- news18— balanced framing, positive sentiment
- economictimes— balanced framing, positive sentiment
- news18— balanced framing, positive sentiment
- indiatoday— balanced framing, positive sentiment
- economictimes— balanced framing, positive sentiment
AI Analysis
The article group presents a largely neutral, business and health-focused perspective, emphasizing Novo Nordisk's product launch and its potential impact on diabetes care in India. Sources include company statements, medical experts, and market data, with no evident political framing or partisan viewpoints. Coverage centers on healthcare innovation and market implications rather than political debate.
The overall tone across the articles is positive and optimistic, highlighting the potential benefits of Awiqli in reducing injection frequency and improving patient adherence. While acknowledging challenges like delayed insulin initiation, the coverage focuses on the innovation's promise to address these issues, reflecting a constructive and forward-looking sentiment.
How 8 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.